These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 27042217)

  • 1. Pretreatment neutrophil-lymphocyte ratio is not a significant prognostic factor in epidermal growth factor receptor-mutant non-small cell lung cancer patients treated with tyrosine kinase inhibitors.
    Sim SH; Beom SH; Ahn YO; Keam B; Kim TM; Lee SH; Kim DW; Heo DS
    Thorac Cancer; 2016 Mar; 7(2):161-6. PubMed ID: 27042217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of clinical parameters and systemic inflammatory status on epidermal growth factor receptor-mutant non-small cell lung cancer patients readministration with epidermal growth factor receptor tyrosine kinase inhibitors.
    Chen YM; Lai CH; Rau KM; Huang CH; Chang HC; Chao TY; Tseng CC; Fang WF; Chung YH; Wang YH; Su MC; Huang KT; Liu SF; Chen HC; Chang YC; Chang YP; Wang CC; Lin MC
    BMC Cancer; 2016 Nov; 16(1):868. PubMed ID: 27821111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pretreatment Lung Immune Prognostic Index Is a Prognostic Marker of Chemotherapy and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor.
    Minami S; Ihara S; Komuta K
    World J Oncol; 2019 Feb; 10(1):35-45. PubMed ID: 30834050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidermal growth factor receptor tyrosine kinase inhibitors vs conventional chemotherapy in non-small cell lung cancer harboring wild-type epidermal growth factor receptor: a meta-analysis.
    Lee JK; Hahn S; Kim DW; Suh KJ; Keam B; Kim TM; Lee SH; Heo DS
    JAMA; 2014 Apr; 311(14):1430-7. PubMed ID: 24715074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of smoking status on the progression-free survival of non-small cell lung cancer patients harboring activating epidermal growth factor receptor (EGFR) mutations receiving first-line EGFR tyrosine kinase inhibitor versus platinum doublet chemotherapy: a meta-analysis of prospective randomized trials.
    Hasegawa Y; Ando M; Maemondo M; Yamamoto S; Isa S; Saka H; Kubo A; Kawaguchi T; Takada M; Rosell R; Kurata T; Ou SH
    Oncologist; 2015 Mar; 20(3):307-15. PubMed ID: 25657199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced chemotherapy sensitivity in EGFR-mutant lung cancer patient with frontline EGFR tyrosine kinase inhibitor.
    Zeng Z; Yan HH; Zhang XC; Zhong WZ; He YY; Guan JL; Niu FY; Xie Z; Huang YS; Xu CR; Dong S; Wu YL
    Lung Cancer; 2014 Nov; 86(2):219-24. PubMed ID: 25263853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Uncommon mutation types of epidermal growth factor receptor and response to EGFR tyrosine kinase inhibitors in Chinese non-small cell lung cancer patients.
    Chen K; Yu X; Wang H; Huang Z; Xu Y; Gong L; Fan Y
    Cancer Chemother Pharmacol; 2017 Dec; 80(6):1179-1187. PubMed ID: 29063948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pretreatment neutrophil-to-lymphocyte ratio is a predictive biomarker for EGFR TKI-treated patients with advanced EGFR-mutant Non-small cell lung cancer.
    Xu C; Yao X; Li T; Wang J; An B; Wang J; Sui X; Leung EL; Wu Q
    Transl Cancer Res; 2020 Apr; 9(4):2875-2883. PubMed ID: 35117644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neutrophil-to-Lymphocyte Ratio Predicts Overall Survival of Advanced Non-Small Cell Lung Cancer Harboring Mutant Epidermal Growth Factor Receptor.
    Minami S; Ogata Y; Ihara S; Yamamoto S; Komuta K
    World J Oncol; 2017 Dec; 8(6):180-187. PubMed ID: 29317963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is There a Survival Benefit of First-Line Epidermal Growth Factor Receptor Tyrosine-Kinase Inhibitor Monotherapy Versus Chemotherapy in Patients with Advanced Non-Small-Cell Lung Cancer?: A Meta-Analysis.
    Guetz GD; Landre T; Uzzan B; Chouahnia K; Nicolas P; Morere JF
    Target Oncol; 2016 Feb; 11(1):41-7. PubMed ID: 26092590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prognostic impact of neutrophil to lymphocyte ratio in advanced non-small cell lung cancer patients treated with EGFR TKI.
    Phan TT; Ho TT; Nguyen HT; Nguyen HT; Tran TB; Nguyen ST
    Int J Gen Med; 2018; 11():423-430. PubMed ID: 30510441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidermal growth factor receptor-tyrosine kinase inhibitor therapy is effective as first-line treatment of advanced non-small-cell lung cancer with mutated EGFR: A meta-analysis from six phase III randomized controlled trials.
    Gao G; Ren S; Li A; Xu J; Xu Q; Su C; Guo J; Deng Q; Zhou C
    Int J Cancer; 2012 Sep; 131(5):E822-9. PubMed ID: 22161771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer Harboring Wild-type Epidermal Growth Factor Receptor: A Meta-analysis of 25 RCTs.
    Sheng Z; Zhang Y
    Am J Clin Oncol; 2017 Aug; 40(4):362-369. PubMed ID: 25647830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neutrophil-to-Lymphocyte Ratio Is a Predictive Biomarker in Patients with Epidermal Growth Factor Receptor (EGFR) Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) Treated with Tyrosine Kinase Inhibitor (TKI) Therapy.
    Yun NK; Rouhani SJ; Bestvina CM; Ritz EM; Gilmore BA; Tarhoni I; Borgia JA; Batus M; Bonomi PD; Fidler MJ
    Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33804721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations.
    Lin JH; Lin D; Xu L; Wang Q; Hu HH; Xu HP; He ZY
    Oncotarget; 2017 Jan; 8(2):3412-3421. PubMed ID: 27926500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of insulin-like growth factor 1 receptor (IGF-1R) predicts poor responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer patients harboring activating EGFR mutations.
    Yeo CD; Park KH; Park CK; Lee SH; Kim SJ; Yoon HK; Lee YS; Lee EJ; Lee KY; Kim TJ
    Lung Cancer; 2015 Mar; 87(3):311-7. PubMed ID: 25617986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gustave Roussy Immune Score Is a Prognostic Factor for Chemotherapy-Naive Pulmonary Adenocarcinoma With Wild-Type Epidermal Growth Factor Receptor.
    Minami S; Ihara S; Komuta K
    World J Oncol; 2019 Feb; 10(1):55-61. PubMed ID: 30834052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive factors for EGFR-tyrosine kinase inhibitor retreatment in patients with EGFR-mutated non-small-cell lung cancer - A multicenter retrospective SEQUENCE study.
    Chang GC; Tseng CH; Hsu KH; Yu CJ; Yang CT; Chen KC; Yang TY; Tseng JS; Liu CY; Liao WY; Hsia TC; Tu CY; Lin MC; Tsai YH; Hsieh MJ; Wu WS; Chen YM
    Lung Cancer; 2017 Feb; 104():58-64. PubMed ID: 28213001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcomes of platinum-based chemotherapy according to T790M mutation status in EGFR-positive non-small cell lung cancer patients after initial EGFR-TKI failure.
    Yoshida T; Kuroda H; Oya Y; Shimizu J; Horio Y; Sakao Y; Hida T; Yatabe Y
    Lung Cancer; 2017 Jul; 109():89-91. PubMed ID: 28577956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Efficacy of Single-Agent Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Biologically Selected Patients with Non-Small-Cell Lung Cancer: A Meta-Analysis of 19 Randomized Controlled Trials.
    Li G; Gao S; Sheng Z; Li B
    Chemotherapy; 2016; 61(4):179-89. PubMed ID: 26859739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.